Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Biomarkers In Cancer Targeted Immunotherapy

Published

on

Delhi, March 15, 2022 (GLOBE NEWSWIRE) — Global Breast Cancer Antibodies Biomarkers & Clinical Trials Insight 2028 Report Highlights:

  • Global Breast Cancer Antibodies Market Opportunity: > USD 15 Billion
  • Breast Cancer Antibodies Clinical Trials Insight: > 150 Drugs In Trials
  • Breast Cancer Biomarkers Sourced During Clinical Trials
  • Breast Cancer Biomarkers Insight By Antibodies  Classification
  • Insight On  Biomarkers Sourced From Trials By Drugs & Indication
  • Biomarker Name & Function Insight By Antibody
  • Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication

Download Report: https://www.kuickresearch.com/ccformF.php?t=1646994975

Global Immune Checkpoint Inhibitors Biomarkers & Clinical Trials Insight 2028 Report Highlights:

  • Global Immune Checkpoint Inhibitors Market Opportunity: > USD 30 Billion
  • Immune Checkpoint Inhibitors Clinical Trials Insight: CTLA-4, LAG3, PD-1/PD-L1, TIGIT Inhibitors
  • Immune Checkpoint Inhibitors Clinical Trials Insight: > 300 Drugs In Trials
  • Biomarkers sourced During clinical Trials
  • Biomarkers Insight By Immune Checkpoint Inhibitors Classification
  • Insight On  Biomarkers Sourced From Trials By Drugs & Indication
  • Biomarker Name & Function Insight By Immune Checkpoint Inhibitor Drug
  • Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication

Download Report:

https://www.kuickresearch.com/report-immune-checkpoint-inhibitors-biomarkers

Biomarkers fall under the category of biological molecules or genes which have their presence in blood and other body fluids. These naturally occurring characteristics are discovered using bioinformatics and play a significant role in finding and understanding diseases and their behaviors. For example, blood pressure, platelets count is biomarkers as they help in the diagnosis of leukemia. Further, the biomarkers can be used for various other reasons including estimating risk of disease, screening for cancer and associated stages, and to determine the response to therapy.

In last few years, immunotherapy has changed the treatment landscape of many different cancer types. There are several different forms of immunotherapy used clinically, including cytokines, antibodies, vaccines, and immune checkpoint inhibitors (ICIs). Although immunotherapeutic approaches have shown encouraging response, they are effective e in approximately 20% to 30% of cancer patients. The majority of patients have no response or are resistant to the treatment, which is largely associated with cold tumors with few or absence of T cells, low tumor mutational burden, and poor antigen presentation. Given this, there is urgent need to develop and validate more accurate biomarkers to assist in patient selection with immunotherapy. The most validated and clinically used biomarkers for immune checkpoint inhibitor response are programmed death-ligand 1 (PD-L1), microsatellite instability/defective mismatch repair (MSI/dMMR), and tumor mutational burden (TMB).

The surge in the demand of cancer biomarkers has propelled the further research and development activities in this domain. Further, the introduction of artificial intelligence has also shown to enhance the search of effective cancer biomarker. For instance, a recent study demonstrated that artificial intelligence-derived digital pathology-based biomarker can help guide treatment decisions for men with localized intermediate-risk prostate cancer. The biomarker ArteraAI-Predict ADT) showed that a majority of men treated with radiation therapy as part of a large randomized phase 3 trial did not require androgen derivation therapy and could have avoided the adverse events and costs associated with that treatment. This is the first validated predictive biomarker for the benefit of ADT with radiotherapy in prostate cancer patients. 

A number of regional and global players operate in this market. These companies compete based on the innovation of their products, their quality, their brand reputation, and their market presence in order to sell their products through various industries. A variety of strategies are being employed by companies to remain competitive. For instance in 2021, US FDA approved first diagnostic kit, Cerascreen KRAS RGQ PCR kit, to identify KRAS G12C mutations in QIAGEN NV NSCLC tumors and expand precision medical options for lung cancer. Further in 2020, Thermo Fisher Scientific signed a contract with to expand the use of the targeted Oncomin-Dx test in patients with non-small cell lung cancer (NSCLC) and accelerate local biomarker testing.

As per our report findings, the global cancer biomarker market will witness exponential growth in coming years. The major driving factors to the market include increase in prevalence of cancer, availability of targeted cancer therapies, rising awareness among population for early diagnosis of cancer, and rising demand of personalized medicine. In addition, increasing regulatory approval of novel drugs and diagnostics pertaining to cancer biomarkers is estimated to increase the adoption rate. The other major players in the market include Abott Laboratories, Amgen, Novartis, Sino Biological, Merck, Agilent Therapeutics, and others.  

The report provides a detailed analysis of ongoing, biomarker-based clinical trials initiated by big pharmaceutical companies. Further, discussion on the upcoming opportunities that is likely to impact the evolution of this market over the coming years. The report also provides a detailed forecast featuring analysis of the current and projected future opportunity across key market segments. 


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

PractiTest Pushes Boundaries of Test Management with Milestones Release

Published

on

practitest-pushes-boundaries-of-test-management-with-milestones-release

REHOVOT, Israel, May 6, 2024 /PRNewswire/ — PractiTest, a leader in innovative test management solutions, continues to push the boundaries with the release of Milestones, a powerful project management module enabling QA teams to align and stay connected to business goals. PractiTest’s New Milestones Module empowers QA teams to define high-level testing objectives within set timeframes. This results in well-defined roadmaps for sprint planning, major releases, or other pivotal project Milestones. By setting these objectives, QA teams gain a focused understanding of their contribution to broader business objectives and deadlines.

“Milestones have given us increased granularity in our ability to organize our testing,” says Tony, a system engineer at Battelle. “Having traceability was good, but Milestones allow us to plan much more clearly and easily.”
Milestones establish a seamless link between QA initiatives and overarching business strategies, ensuring testing efforts directly contribute to achieving company objectives. By defining clear testing objectives and schedules for each project phase, QA teams can stay on track and ensure efficient use of resources. The Milestones module also improves visibility, providing a high-level overview of the entire testing process and promoting seamless communication and collaboration among cross-functional teams.
PractiTest’s Commitment to Innovation
The release of Milestones reaffirms PractiTest’s dedication to providing cutting-edge solutions that empower QA teams to thrive.
“In today’s competitive environment, ensuring QA aligns with business objectives is imperative,” says Yaniv Iny, CEO of PractiTest. “The Milestones module is a testament to our commitment to empowering QA teams to evolve into strategic partners, fostering quality and delivering tangible outcomes while staying in sync with overarching business objectives.”
About PractiTest
PractiTest is an end-to-end test management platform designed to simplify and untangle complexity for complex and robust environments. PractiTest centralizes all your QA work, processes, teams, and tools into one platform to bridge silos, unify communication, and enable one source of truth across your organization. With PractiTest you can make informed data-driven decisions based on end-to-end visibility provided by customizable reports, real-time dashboards, and dynamic filter views.
For more information about PractiTest visit: https://www.practitest.com/
Media Contact:May [email protected]
Logo: https://mma.prnewswire.com/media/1997506/PractiTest_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/practitest-pushes-boundaries-of-test-management-with-milestones-release-302136603.html

Continue Reading

Artificial Intelligence

EZVIZ unveils its groundbreaking H9c Dual-lens Smart Pan-and-tilt Camera series: a new paradigm for automated, all-round outdoor protection

Published

on

ezviz-unveils-its-groundbreaking-h9c-dual-lens-smart-pan-and-tilt-camera-series:-a-new-paradigm-for-automated,-all-round-outdoor-protection

By combining a pan-and-tilt panoramic lens and a fixed 180-degree wide-angle lens, one H9c Dual smartly secures large areas with performance better than that of two ordinary ones.
HOOFDDORP, Netherlands, May 6, 2024 /PRNewswire/ — EZVIZ, a leading global player in innovative smart home security, proudly introduces the H9c Dual series, its latest dual-lens outdoor pan-and-tilt cameras that redefine smart protection for homes and small businesses. With options in 2K and 3K resolutions, their groundbreaking design combines a sharp bullet camera and a flexible PT camera, addressing complex security needs effectively. The interlinked dual lenses work collaboratively to safeguard wide property areas, detect and track activities, and offer auto-patrol options for hands-free security.

“The H9c Dual challenges traditional outdoor cameras with unrivaled vision, unmatched automation, and high versatility for basically any scenario,” said Candice Tu, the lead product manager, “EZVIZ leads the way in the development and application of advanced dual-lens technology. This underlines our dedication to bringing cutting-edge technology within reach for practical, everyday situations.”
At the core of the H9c Dual is its groundbreaking dual-lens technology, highlighted by EZVIZ’s distinctive co-action function. The two lenses can work independently at two static viewing angles or act together as a team. When the fixed lens detects motions, the pan-and-tilt lens automatically rotates to track the same activity. This co-action function can also be manually controlled through the EZVIZ App.
The series addresses unnoticed blind spots by offering a 180-degree comprehensive view in a single frame, supplemented by the bottom PT lens for intricate close-ups. Both lenses, with high resolutions of 2K/3K, use built-in AI chips to detect people and vehicles in customizable zones, ensuring users are informed of crucial activities. Users can set up to four patrol spots for the PT lens to complete automatic rotations on a schedule.
Equipped with powerful LEDs, the H9c Dual provides color night vision up to 40 meters and warns potential trespassers with a loud siren and dazzling flashlight upon detection. Offering superior protection compared to a traditional two-camera system, the H9c is a breeze to set up thanks to its adaptable mounting design. Users can manage and control their H9c through the user-friendly EZVIZ App, and enjoy seamless integration with prevailing voice assistants and the larger EZVIZ ecosystem.
Learn more at www.ezviz.com.
Photo – https://mma.prnewswire.com/media/2404810/EZVIZ_H9c_Dual_Lens_Pan_Tilt_Wi_Fi_Camera.jpg

View original content:https://www.prnewswire.co.uk/news-releases/ezviz-unveils-its-groundbreaking-h9c-dual-lens-smart-pan-and-tilt-camera-series-a-new-paradigm-for-automated-all-round-outdoor-protection-302136133.html

Continue Reading

Artificial Intelligence

Red light therapy for repairing spinal cord injury passes milestone

Published

on

red-light-therapy-for-repairing-spinal-cord-injury-passes-milestone

BIRMINGHAM, England, May 6, 2024 /PRNewswire/ — Patients with spinal cord injury (SCI) could benefit from future treatment to repair nerve connections using red and near-infrared light.

The method, invented by University of Birmingham scientists and patented by University of Birmingham Enterprise, delivers light directly to the site of the injury. 
Their latest research, published in Bioengineering and Translational Medicine, determined an optimal ‘dose’ for this novel approach, and showed it can deliver therapeutic improvements including significant restoration of sensation and movement, and regeneration of damaged nerve cells. 
Researchers led by Professor Zubair Ahmed used cell models of SCI to determine the frequency and duration of light required to achieve maximum restoration of function and stimulate nerve cell regrowth. 
They found delivery at a wavelength of 660nm for one minute a day increased cell viability (the number of live cells) by 45% over five days’ treatment. 
Professor Ahmed said: “The effect of 660nm light was both neuroprotective, meaning it improved survival of nerve cells, and neuroregenerative, meaning it stimulated nerve cell growth.” 
The researchers also investigated the effect of light therapy in preclinical models of SCI, using an implantable device and transcutaneous delivery with the light source placed against the skin. They showed comparable results for both methods, with a one-minute dose of 660nm light, delivered daily for seven days resulting in reduced tissue scarring, increased levels of proteins associated with nerve cell regeneration, improvements in the connections between cells and significant functional recovery. 
This is the first time transcutaneous and direct light delivery have been compared in SCI. Professor Ahmed said: “To make light therapy viable for treating SCI in humans an implantable device will be required, to provide line of sight to damaged tissue and the opportunity for greater accuracy and standardise dosing without impedance due to the thickness of the skin and other tissues surrounding the spinal cord.”
The researchers are planning to develop an implantable device for use in humans with traumatic SCI. They have already received further funding and are seeking commercial partners or investors to develop a prototype device to take into first-in-man clinical trials.
Full release here. 
University of Birmingham Enterprise helps researchers turn ideas into products and services that meet real-world needs. Follow us on LinkedIn and X.
Photo: https://mma.prnewswire.com/media/2404909/University_of_Birmingham_Enterprise.jpg
Media enquiries: Ruth Ashton
Commercial enquiries: Veemal Bhowruth

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/red-light-therapy-for-repairing-spinal-cord-injury-passes-milestone-302136233.html

Continue Reading

Trending